Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Scholar Rock Holding Corp

SRRK ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$52.52

▼ -1.02%

Market Cap $6.40B · Vol 197.17K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.40B

Mid Cap

Div Yield

N/A

EPS Growth

+1.98%

YoY

RSI (14)

61.74

Momentum

Beta

0.68

vs Market

52W High

$58.09

9.59% below

52W Low

$27.10

93.80% above

Volume

197.17K

Avg 355.13K

P/B

19.46

Price-to-book

ROE

-123.08%

Return on equity

Free Float

99.04%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Scholar Rock Holding Corp (SRRK) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SRRK pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.76%

-2.34%

+2.42%

+14.22%

YTD

+19.23%

+62.65%

+661.16%

+33.91%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-377,939,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-123.08%
ROA · ROIC	-85.97% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	19.46
P/FCF	N/A
EPS Growth	+1.98%
Outstanding Shares	121.79M

Technical Indicators

50-Day SMA	$50.55
200-Day SMA	$45.76
RSI (14)	61.74
Beta	0.68
52-Week High	$58.09
52-Week Low	$27.10

Volume Today	197.17K
Avg Daily Volume (30D)	355.13K
Relative Volume	0.56x
Volatility (10D)	55.75
Volatility (30D)	48.49
Free Float	99.04%

Analyst Consensus

BUY

Current Price $52.52

Mean Target $60.20

52W Low$27.10 52W High$58.09

Current

Target

$27.10 $58.09

Current Analyst target

+14.62% upside potential · 18 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00KT2RSD4

ISINUS80706P1030

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.